menu
    • menu

    Company profile for Breckenridge Pharmaceutical

    Towa Pharmaceutical-PSE
    News
    Breckenridge Gets FDA Nod For Everolimus Oral Suspension

    29 Jan 2025

    // PR NEWSWIRE

    Enforcement Report - Week of January 1, 2025

    01 Jan 2025

    // FDA

    Breckenridge Receives FDA Approval for Methadone HCl Injection

    18 Dec 2024

    // PR NEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Breckenridge Pharmaceutical

    Contact Supplier

    Website

    Biotech Digital Meet

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/fda-s-first-generic-approvals-slump-21-in-2024-novartis-top-seller-entresto-cancer-blockbuster-tasigna-lead-2024-patent-cliff

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Breckenridge Pharmaceutical, Inc. is a Towa Company. We are an own label distributor that performs pharmaceutical marketing, sales and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in several therapeutic categories and dosage forms, including tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders, transdermal patches, and injectable products. The Breckenridge label is recognized nationwide by wholesalers, distributors, chains, managed care accounts, and retail pharmacies. Breckenridge, headquartered in Berlin, Connecticut.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Breckenridge PharmaceuticalUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    15 Massirio Drive, Suite 201 Berlin, CT 06037
    Telephone
    Telephone
    +1 8608288140
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.bpirx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/breckenridge-pharmaceutical
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Breckenridge Gets FDA Nod For Everolimus Oral Suspension
    Breckenridge Gets FDA Nod For Everolimus Oral Suspension

    29 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/breckenridge-announces-final-fda-approval-for-everolimus-tablets-for-oral-suspension-ab-rated-to-afinitor-disperz-302363514.html

    PR NEWSWIRE
    29 Jan 2025
    Share Share
    Enforcement Report - Week of January 1, 2025
    Enforcement Report - Week of January 1, 2025

    01 Jan 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-1-2025-88420.pdf

    FDA
    01 Jan 2025
    Share Share
    Breckenridge Receives FDA Approval for Methadone HCl Injection
    Breckenridge Receives FDA Approval for Methadone HCl Injection

    18 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/breckenridge-announces-final-fda-approval-for-methadone-hydrochloride-multi-dose-injection-302334969.html

    PR NEWSWIRE
    18 Dec 2024
    Share Share
    Enforcement Report - Week of June 26, 2024
    Enforcement Report - Week of June 26, 2024

    26 Jun 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-26-2024-3489.pdf

    FDA
    26 Jun 2024
    Share Share
    Enforcement Report - Week of May 15, 2024
    Enforcement Report - Week of May 15, 2024

    15 May 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-15-2024-59166.pdf

    FDA
    15 May 2024
    Share Share
    Breckenridge Pharma`s Generic Rivaroxaban Receives Approval in the U.S.
    Breckenridge Pharma`s Generic Rivaroxaban Receives Approval in the U.S.

    24 Jan 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208220

    FDA
    24 Jan 2024
    Share Share

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search